Dosing & Uses
Dosage Forms & Strengths
tablet
- 250mg
Carcinoid Syndrome Diarrhea
Indicated in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy
250 mg PO TID
Also, see Administration
Dosing Modifications
Renal impairment:
- Mild, moderate, or severe renal impairment not requiring dialysis: No dosage adjustment necessary
- End-stage renal disease requiring dialysis (eGFR< 15 mL/min/1.73 m²): Not studied
Hepatic impairment:
- Mild (Child-Pugh A): No dosage adjustment necessary; however, additional monitoring of associated adverse reactions (eg, constipation) recommended
- Moderate (Child-Pugh Class B) to severe (Child-Pugh C): Not recommended
Safety and efficacy not established
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Adverse Effects
>10%
Nausea (13%)
Headache (11%)
1-10%
Increased GGT (9%)
Depression (9%)
Peripheral edema (7%)
Flatulence (7%)
Decreased appetite (7%)
Pyrexia (7%)
Abdominal pain (5%)
Constipation (5%)
Increased alkaline phosphatase (<5%)
Increased ALT and AST (<5%)
Warnings
Contraindications
None
Cautions
Reduces bowel movement frequency; monitor for development of constipation and/or severe, persistent, or worsening abdominal pain; discontinue if severe constipation or severe persistent or worsening abdominal pain develops
Drug interaction overview
- Telotristat ethyl induces CYP3A4 and may reduce systemic exposure of sensitive CYP3A4 substrates
- Short-acting octreotide decreases telotristat Cmax and AUC by 79% and 68%, respectively; administer octreotide at least 30 minutes after telotristat ethyl (also see Administration)
Pregnancy
Pregnancy
There are no human data in pregnant women to inform a drug-associated risk
Animal studies
- No effects on embryo-fetal development were observed with administration of telotristat ethyl to rats during organogenesis at doses up to 750 mg/kg/day (~9 times the exposure at recommended human dose [RHD])
- Treatment of pregnant rabbits during organogenesis produced maternal toxicity and postimplantation loss at doses of ≥250 mg/kg/day (~15 times the exposure at the RHD), and reduced fetal weight at 500 mg/kg/day (~33 times the exposure at the RHD)
Lactation
Unknown if distributed in human breast milk
Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition
If administered to a breastfeeding woman, monitor infant for constipation
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Telotristat, the active metabolite of telotristat ethyl, inhibits tryptophan hydroxylase, which mediates the rate-limiting step in serotonin biosynthesis
Serotonin plays a role in mediating secretion, motility, inflammation, and sensation of the GI tract, and is overproduced in patients with carcinoid syndrome
In vitro inhibitory potency of telotristat towards tryptophan hydroxylase is 29 times higher than that of telotristat ethyl
Absorption
Peak plasma time: 1 hr (telotristat ethyl); 2 hr (telotristat)
Peak plasma concentration: 7 ng/mL (telotristat ethyl); 900 ng/mL (telotristat)
AUC: 22 ng·hr/mL (telotristat ethyl); 3000 ng·hr/mL (telotristat)
Administration with food significantly increases systemic exposure of telotristat ethyl and telotristat
Distribution
Protein bound: >99% (both telotristat ethyl and telotristat)
P-gp substrate
Metabolism
Telotristat ethyl undergoes hydrolysis via carboxylesterases to telotristat, its active metabolite
Telotristat is further metabolized
Telotristat ethyl and telotristat are not substrates for CYP enzymes
Elimination
Half-life: 0.6 hr (telotristat ethyl); 5 hr (telotristat)
Total clearance: 2.7 L/hr (telotristat ethyl); 152 L/hr (telotristat)
Excretion: <0.4% urine; 92.8% feces
Administration
Oral Administration
Take with food
When used in combination with short-acting octreotide, administer short-acting octreotide at least 30 minutes after telotristat ethyl
Discontinue if severe constipation develops
Missed dose
- If a dose is missed, take the next dose at the regular time
- Do not take 2 doses at the same time to make up for a missed dose
Storage
Store at controlled room temperature (25°C [77°F])
Excursions permitted to 15-30°C (59-86°F)
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
